Inflammation linked to weakened reward circuits in depression

November 20, 2015
Inflammation linked to weakened reward circuits in depression
What does inflammation in the context of depression look like inside the brain? Emory researchers have found that high inflammation is linked to a "failure to communicate" between two parts of the brain: the ventral striatum (VS, vertical cross section) and the ventromedial prefrontal cortex (vmPFC, horizontal). Credit: Felger et al, Molecular Psychiatry (2015)

About one third of people with depression have high levels of inflammation markers in their blood. New research indicates that persistent inflammation affects the brain in ways that are connected with stubborn symptoms of depression, such as anhedonia, the inability to experience pleasure.

The results were published online on Nov. 10 in Molecular Psychiatry.

The findings bolster the case that the high-inflammation form of depression is distinct, and are guiding researchers' plans to test treatments tailored for it.

Anhedonia is a core symptom of depression that is particularly difficult to treat, says lead author Jennifer Felger, PhD, assistant professor of psychiatry and behavioral sciences at Emory University School of Medicine and Winship Cancer Institute.

"Some patients taking antidepressants continue to suffer from anhedonia," Felger says. "Our data suggest that by blocking inflammation or its effects on the brain, we may be able to reverse anhedonia and help depressed individuals who fail to respond to antidepressants."

In a study of 48 patients with depression, high levels of the inflammatory marker CRP (C-reactive protein) were linked with a "failure to communicate", seen through brain imaging, between regions of the brain important for motivation and reward.

Neuroscientists can infer that two regions of the brain talk to each other by watching whether they light up in magnetic resonance imaging at the same times or in the same patterns, even when someone is not doing anything in particular. They describe this as "functional connectivity."

In patients with high CRP, Felger and her colleagues observed a lack of connectivity between the ventromedial prefrontal cortex and the ventral striatum. In contrast, patients with low CRP had robust connectivity, they write.

"We were interested in these regions of the brain because of their known importance for response to reward," she says. "In addition, we had seen reduced activation of these areas in people receiving immuno-stimulatory treatments for hepatitis C virus or cancer, which suggested that they may be sensitive to inflammation."

High CRP levels were also correlated with patients' reports of anhedonia: an inability to derive enjoyment from everyday activities, such as food or time with family and friends. Low connectivity between another region of the striatum and the was linked to a different symptom: slow motor function, as measured by finger tapping speed.

During the brain imaging portion of the study, participants were not taking antidepressants, anti-inflammatory drugs or other medications for at least four weeks, and CRP was measured on repeat visits to make sure its levels were stable. High CRP was also correlated with BMI (body mass index), but the statistical relationship was strong even after correcting for BMI and other variables such as age.

A previous study of people with difficult-to-treat depression found that those with high inflammation (as measured with CRP), but not other participants in the study, improved in response to the anti-inflammatory antibody infliximab.

As a next step, Felger is planning to test whether L-DOPA, a medicine that targets the brain chemical dopamine, can increase connectivity in reward-related regions in patients with high-inflammation depression. This upcoming study is being supported by the Dana Foundation.

Felger's previous research in non-human primates suggests that inflammation leads to reduced dopamine release. L-DOPA is a precursor for dopamine and often given to people with Parkinson's disease.

"We hope our investigations may lead to new therapies to treat anhedonia in high-inflammation ," she says.

Explore further: Targeting inflammation to treat depression

More information: J C Felger et al. Inflammation is associated with decreased functional connectivity within corticostriatal reward circuitry in depression, Molecular Psychiatry (2015). DOI: 10.1038/mp.2015.168

Related Stories

Targeting inflammation to treat depression

September 3, 2012

Researchers at Emory University have found that a medication that inhibits inflammation may offer new hope for people with difficult-to-treat depression. The study was published Sept. 3 in the online version of Archives of ...

Inflammation in depression: Chicken or egg?

January 5, 2012

An important ongoing debate in the field of psychiatry is whether inflammation in the body is a consequence of or contributor to major depression. A new study in Biological Psychiatry has attempted to resolve the issue.

Uncovering the source of inflammatory malaise

October 22, 2012

(Medical Xpress)—A study conducted by researchers at Emory indicates that inflammation targets a part of the brain called the basal ganglia, causing symptoms of depression and fatigue. The study was recently reported in ...

CRP/ESR disagreement common in infection, inflammation

January 16, 2015

(HealthDay)—For patients with suspected infection or inflammation, C-reactive protein (CRP)/erythrocyte sedimentation rate (ESR) disagreement is common, according to a study published online Dec. 31 in the International ...

Recommended for you

Game study not playing around with PTSD relief

May 26, 2017

Post-traumatic stress disorder (PTSD) patients wrestling with one of its main symptoms may find long-term relief beyond medication thanks to the work of a Western researcher.

Bouldering envisioned as new treatment for depression

May 25, 2017

A growing body of research suggests that bouldering, a form of rock climbing, can help build muscle and endurance while reducing stress—and a new study co-led by a University of Arizona doctoral student of psychology suggests ...

Study documents range of challenging meditation experiences

May 24, 2017

Meditation is increasingly being marketed as a treatment for conditions such as pain, depression, stress and addiction, and while many people achieve therapeutic goals, other meditators encounter a much broader range of experiences—sometimes ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.